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Several evidences suggest that NK cells can patrol the body and eliminate tumors in their initial phases but may hardly control
established solid tumors. Multiple factors, including the transition of tumor cells towards a proinvasive/prometastatic phenotype,
the immunosuppressive effect of the tumor microenvironment, and the tumor structure complexity, may account for limited NK
cell efficacy. Several putative mechanisms of NK cell suppression have been defined in these last years; conversely, the cross talk
between NK cells and tumor cells undergoing different transitional phases remains poorly explored. Nevertheless, recent in vitro
studies and immunohistochemical analyses on tumor biopsies suggest thatNK cells could not only kill tumor cells but also influence
their evolution. Indeed, NK cells may induce tumor cells to change the expression of HLA-I, PD-L1, or NKG2D-L and modulate
their susceptibility to the immune response. Moreover, NK cells may be preferentially located in the borders of tumor masses,
where, indeed, tumor cells can undergo Epithelial-to-Mesenchymal Transition (EMT) acquiring prometastatic phenotype. Finally,
the recently highlighted role of HMGB1 both in EMT and in amplifying the recruitment of NK cells provides further hints on a
possible effect of NK cells on tumor progression and fosters new studies on this issue.
1. Introduction
NK cells are Innate Lymphoid Cells (ILCs) that play a
crucial role in the defense against viruses and in the surveil-
lance of tumor insurgence [1–5]. In view of their possible
exploitation in cancer (but also in viral infections), these
cells have been intensively studied, so that the molecular
mechanisms regulating their antitumor cytolytic activity have
been extensively defined. By the use of a wide array of
surface receptors capable of delivering either triggering or
inhibitory signals, NK cells can monitor surrounding cells,
checking for their possible phenotypic alterations, and tune
an appropriate cytolytic response. In humans, these receptors
are essentially represented by the following: (1) the HLA-I-
specific inhibitory receptors, Killer Ig-like Receptors (KIR),
and CD94:NKG2A receptor, which prevent NK cells from
attacking normal autologous cells, and (2) a number of
activating receptors (including NKG2D, DNAM-1, and the
Natural Cytotoxicity Receptors (NCRs): NKp46, NKp30, and
NKp44), which recognize ligands expressed on the surface of
transformed and/or virally infected cells and enable NK cells
to kill abnormal cells [3, 6].
Most of the above-mentioned receptors are also involved
in the control of additional functions exerted by NK cells
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ranging from the release of cytokines and chemokines
(namely, IFN-𝛾, TNF-𝛼, GM-CSF, MIP1-𝛼, and RANTES)
[3, 7] to the regulatory interactionswith different immune cell
types including Dendritic Cells (DCs), macrophages, mono-
cytes, granulocytes, and T cells [3, 8–12]. Moreover, NK cells
are endowed with additional diverse receptors that enable
them to respond to a variegated plethora of stimuli. Thus,
NK cells can variably potentiate their functions in response
to several Pathogen Associated Molecular Patterns (PAMPs)
by using different TLRs (i.e., TLR2, TLR3, TLR7, and TLR9)
[13, 14]; they can strongly increase their cytokine production
and/or their cytolytic properties in response to different
cytokines including IL-2, IL-15, IL-12, IL-18, and IFNs 𝛼/𝛽
[3, 15]; and finally, they can alsomigrate in response to various
chemotactic stimuli (see below). Twomain NK cell functions
(i.e., cytotoxicity and IFN-𝛾 production) appear to be differ-
ently distributed among specific NK cell subsets in Peripheral
Blood (PB) andLymphNodes (LN).The so-called “terminally
differentiated” PB CD56dimCD16bright NK cells expressing
CD57 and KIR molecules display a high cytotoxic potential
and a limited ability to secrete IFN-𝛾 upon cytokine stimu-
lation. The CD56dimCD16brightCD57−KIR−NKG2A+ PB NK
cells exert both functions at intermediate levels. Finally, less
differentiated CD56brightCD16dim/negCD57−KIR−NKG2A++
NK cells, which preferentially locate in LN and are poorly
represented in PB, show low cytotoxicity and high IFN-𝛾
release upon cytokine stimulation [15–18]. Remarkably, it has
been also proposed that NK cells may adapt their cytolytic
potential to the pattern of NK receptor ligands (NKR-Ls)
stably expressed in the milieu. Thus, the chronic exposure
to activating ligands or to abnormally low levels of MHC-
I molecules (i.e., inhibitory ligands) would render NK cells
poorly reactive. On the other hand, the exposure to adequate
MHC-I levels would increase NK cell reactivity and would be
essential for differentiated KIR+ NK cells to become fully
competent [19].
This brief description of the NK cell biology indicates that
these cells are far frombeing simple cytolytic effectors capable
of killing different tumor cell targets; rather, they represent a
heterogeneous population that is able to fulfill different func-
tions and to finely tune its activity in variable environmental
contexts. Such emerging complexity renders the exploitation
of NK cells for effective immunotherapies more complicated
than initially thought, especially in the context of solid
tumors. Indeed, while different animal models and a follow-
up study support the notion that NK cells can survey and
control the insurgence of tumors [20–22], a straightforward
role of NK cells in the control of advanced established solid
tumors is far from being defined. In this context the specific
tumor associated microenvironment evolving along with the
progression of the malignancy may play a role. On the one
hand, the increasing tumor structure complexity and the
tumor microenvironment can heavily affect NK cell behavior
and limit NK cell infiltration of the tumor mass; on the other
hand, NK cells that successfully reach (or develop within) the
tumor site may interact with different cell populations and
influence the progression of the tumor. In the past few years,
the suppressive effects of the tumor microenvironment on
NK cells have been widely studied [23, 24]. A number of
soluble factors [25–28], as well as different tumor associated
regulatory/suppressive immune cells [29, 30], Tumor Associ-
ated Fibroblasts (TAFs) [31], and tumor cells [32, 33], have
been shown to profoundly alter the expression and/or the
function of several NK cell receptors and affect the ability
of NK cells to reach, recognize, and kill tumor cells at the
tumor site (Table 1). Conversely, the possible effect of NK
cells on tumor progression is still poorly investigated. In this
context, recent evidences indicate that NK cells are capable of
modifying the immunogenicity of cancer cells (see below).
The structure of tumor tissue is rather complex and
encompasses hypoxic niches, vascularized areas, necrotic
zones, and a front of tumor invasion. Along this front, several
tumor cells can acquire a less differentiated prometastatic
phenotype through a transitional process that in tumors of
epithelial origin is referred to as Epithelial-to-Mesenchymal
Transition (EMT) (or EMT-like process in melanomas) [48–
50]. Thus, the positioning of NK cells within the tumor and
their possible conditioning in a hypoxic environment [51]
represent important additional elements to be considered in
order to define the role of NK cells in the progression of
tumor. In this context High Mobility Group Box-1 (HMGB1)
[52] may represent a link between NK cells and tumor cell
progression. Indeed, recent studies have provided evidence
for a role of HMGB1 in the induction of the EMT [53], while
in our lab we have recently shown that HMGB1 is actively
released during NK:melanoma cell interaction and can
amplify recruitment of NK cells.
In this review we analyze the current information sug-
gesting a possible role for infiltratingNK cells in the evolution
of tumor cells towards more malignant stages. In this context
we also discuss HMGB1 as a possible key-player linking NK
cells to the plasticity of tumor cells.
2. NK Cells and the Progression of
Cell Tumorigenesis
2.1. The Process of Tumorigenesis and Tumor Cell Plasticity.
Normal cell growth and death are tightly controlled processes
that ensure the maintenance of tissue homeostasis in the
body. The occurrence of random mutations affecting key
suppressor genes, oncogenes, and genes involved in DNA
repair can alter such homeostatic status, leading to uncon-
trolled cell growth, immortality, and, finally, tumor onset.
In solid tumors the specific microenvironment may enhance
the genetic and epigenetic instability of evolving tumor cells,
favoring the accumulation of mutations and the progression
towards a proinvasive and prometastatic phenotype. Epi-
genetic changes may contribute to late evolution steps by
conferring phenotypic and functional plasticity to tumor cells
[48, 54].The acquisition of plasticity is relevant to the capacity
of tumor cells to leave the primary tumor, spread to distant
organs through the blood stream or the lymphatic system,
and create metastases [55]. In cancers of epithelial origin,
tumor cells must lose their epithelial characteristics (polarity,
cell-to-cell adhesion, etc.) and gain mesenchymal traits that
allow them to detach from the primary site and invade both
neighboring and distant tissues. Acquisition ofmigrating and
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Table 1: NK cell infiltrate in solid tumors.
Tumor NK cell infiltrate: phenotype NK cell infiltrate: size and/or location Ref.
Lung
adenocarcinoma
Reduced expression of NKp30, NKp46 [34]
Enrichment of CD56bright Perflow poorly cytotoxic
NK cells [35]
Non-small cell lung
cancer
CD56brightCD16dim infiltrating NK cells with
impaired killing capability [36]
Infiltrating CD56dim with low activating NK-rec
expression and function
NKp46+ cells mainly localized at the
invasive margin [37]
Melanoma (primary) Moderate/low CD56+CD3− cells [32]
Melanoma
(primary/metastases) Low CD56
+NKG2D+ NK cells [38]
Melanoma
(metastases) Low CD56
+ NK cells [21]
Melanoma
(nodal/skin
metastases)
CD56+ NK cells rarely present in
melanoma [39]
Melanoma (nodal
metastases)
NKp30, NKG2D expression inversely correlated with
number of tumor cells in the LN NK cells surround tumor cell cluster [40]
Melanoma (nodal
metastases)
Enrichment of CD56dim KIR+CD57+
cytotoxic NK cells [41]
Colorectal cancer Scarce NKp46
+ infiltrating NK cells
(despite high levels of chemokines) [42]
Colorectal cancer Reduced NKp46, NKp30, DNAM-1 expression [43]
Colorectal cancer
(lung metastases) Low NKp46
+ NK cell infiltrate [44]
Breast cancer
Expression/function of NKp30, NKG2D in
infiltrating NK cells decreases with disease
progression
[45]
Breast cancer Enrichment of CD56
bright Perflow poorly cytotoxic
NK cells [35]
Renal cell carcinoma
(lung metastases)
High NKp46+ NK cell infiltrate
correlates with improved survival [44]
GIST
(GastroIntestinal
Stromal Tumors)
Substantial NKp46+ NK cell infiltrate
mainly surrounding tumor nests [46]
GIST
(GastroIntestinal
Stromal Tumors)
Low NK cell infiltration/high
metastases at diagnosis [46]
GIST
(GastroIntestinal
Stromal Tumors)
High NK cell infiltration/prolonged
progression-free survival after
imatinib treatment
[47]
invasive properties, as well as turning back into an epithelial
phenotype to establish micrometastases, implies a vast cell
reprogramming that borrows the molecular pathways from
the latent developmental program known as Epithelial-to-
Mesenchymal Transition/Mesenchymal-to-Epithelial Transi-
tion (EMT/MET) [48].
2.2. The EMT and Its Possible Relationship with the Immune
System. The induction of EMT seems to be rather tissue-
specific and is governed by complex networks. TGF-𝛽-,Wnt-,
Notch-, and growth factor receptor-induced signaling cas-
cades are the main inducers of the EMT; not coincidentally,
most of these pathways are overactivated in carcinomas and
have been associated with the acquisition of an invasive phe-
notype [55, 56]. In addition, recent studies have demonstrated
that adverse cellular conditions, such as hypoxia or some
components of the extracellular matrix (i.e., collagen and
hyaluronic acid), can also induce EMT in some cancer types
[57–59].
Despite their complexity, the EMT-inducing pathways
have a common endpoint in the activation of a short list
of EMT-inducing transcription factors (TF) (including Snail,
Slug, zinc finger E-box binding homeobox 1 (ZEB1), Twist,
Goosecoid, and FOXC2) and MET-inducing microRNAs
(miR200 and miR34) that orchestrate the phenotype switch
[60]. The consequence of the activation of all these TF is the
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transcriptional repression of cellular junction proteins, such
as E-cadherin, claudins, and ZO-1, causing the loss of epithe-
lial integrity and also the activation of programs associated
with tumor invasion [61–65]. Instead, noncoding microR-
NAs,microRNA200 (miR200) andmiR205, operate theMET
process inhibiting the repressors of E-cadherin expression,
ZEB1 and ZEB2, and thereby maintaining the epithelial cell
phenotype [66, 67].
Importantly, the recent advances in the characterization
of tumor cell plasticity and phenotype switching on epithelial
and nonepithelial tumors (i.e., melanomas) suggest that the
EMT-MET could be part of a wider, complex transitional
phenomenon, in which tumor cells may fluctuate from a
differentiated, proliferative, poorly invasive, drug sensitive
phenotype to an undifferentiated, poorly proliferative, proin-
vasive, drug resistant phenotype [68–71]. Thus, tumor cell
plasticity and its regulation appear to be a nodal point in
the tumor progression and spread; consequently, targeting
this phenomenon may be crucial for the immune system to
control the fate of the tumor.
Immune cells may have a dual role in carcinogenesis
[71, 72]. While a powerful antitumor immune response often
occurs to control the first steps of malignant transformation
[73–75], in the later tumor stages, transformed cells may
manage not only to counteract the immune function but
also to use it as an ally in tumor progression [76]. In
this context, recent studies have shown that EMT could
be locally associated with the presence of granulocytes,
Tregs, M2 macrophages, or MDSC, indicating a role for
different immune cell types in EMT induction [77–82].These
studies also suggest that EMT may preferentially induce or
be induced by suppressive immune cells. Moreover, EMT
may directly confer mesenchymal-like immune-modulatory
features to tumor cells [83]. Finally, EMTmay alsomodify the
immunogenicity of cancer cells, favoring their escape from
the T cell-mediated attack (immunoediting) [72, 84, 85]. A
link between immunoediting and EMT promotion has been
investigated in syngeneic immune-competent mice trans-
planted with epithelial cancers expressing the neu-oncogene
[84]. As expected, the immune surveillance resulted in a
macroscopic elimination of the tumor that however was
not complete. Indeed, tumor relapse occurred and the new
lesions were enriched in neu-negative malignant cells with a
mesenchymal phenotype.
Given the potential antitumor and antimetastatic effect
of NK cells, an important (still open) question is whether
and how NK cells could functionally interact with cells
undergoing EMT and how relevant this potential interaction
could be to the control of the malignancy.
2.3. NK Cells and EMT. Themutual influence between EMT
andNK cells has been barely investigated until now. Only few
studies address the issue of the potential changes in tumor
immunogenicity during EMT and its implications for NK
cell-mediated responses.
In a recent study, Lo´pez-Soto and colleagues described
a significant upregulation of NKG2D activating ligands in
colon cancer cells undergoing EMT, as well as a remarkable
downregulation of HLA-I expression. They proposed that
the EMT could enhance cancer cell immunogenicity towards
NK cells and favor tumor clearance in a NKG2D-dependent
manner. They also showed that the expression of MICA/B
proteins (the main ligands for the NKG2D receptor) was
very low in advanced in vivo tumors with invasive properties.
Concomitantly, a greater presence of NKG2D+ cytotoxic
Tumor-Infiltrating Lymphocytes (TILs) was observed in
these samples. These results suggested that NK cells, through
the engagement of NKG2D receptor, might be responsible for
the elimination ofMICA/B-expressing transitional cells, thus
exerting an immunoediting of tumor cells by the selection
of less immunogenic variants [86, 87]. In line with these
data, Chen and colleagues showed that prostate cancer
cells strongly downregulate HLA-I expression during TGF-
𝛽/EGF-induced EMT in a Snail-dependent manner. This
phenotypic change might render tumor cells resistant to
cytotoxic T cell-mediated lysis but might also increase their
susceptibility to NK cell-mediated responses. On the other
hand, TGF-𝛽, besides inducing EMT, could also suppress NK
cells and compensate the effect of the decreased resistance to
NK cells acquired by transitional tumor cells [88].
Compelling evidences indicate that the invasive behavior
of tumor cells may be strongly influenced by nearby stromal
and immune cells. Nonetheless, regarding the possible effect
of NK cells on the induction or inhibition of EMT there are
presently no direct data. However, different studies indicated
that NK cells can modulate the phenotype of tumor cells and
modify their immunogenicity to eitherNKorT cells.Wehave
recently shown that NK cells can induce HLA-I upregulation
on the surface of melanoma cells and confer resistance to NK
cell-mediated killing [89]. By coculturing melanoma and NK
cells at ratios reflecting the level ofNK cell infiltrates observed
at the tumor site, we described that the initial tumor cell
killing was followed by an equilibrium phase characterized
by the upregulation on melanoma cells of both classical and
nonclassical HLA-I molecules. This effect was mediated by
IFN-𝛾, which was released by NK cells upon melanoma cell
recognition. This NK cell-mediated immunoediting recalls
the so-called “adaptive immune resistance,” a process in
which cancer cells adapt their phenotype under the pres-
sure of the immune response in order to evade it. This
phenomenon was hypothesized by Taube and coworkers to
describe the acquisition of the inhibitory ligand PD-L1 by
tumor cells. In particular, this study showed a clear associ-
ation between the presence of TILs and IFN-𝛾 close to tumor
cells and PD-L1 expression [90]. Thus, the activation of TILs
and the consequent release of IFN-𝛾 (but also the expression
of IL-10 and IL-32-gamma in the tumor tissue)would result in
upregulation of PD-L1 expression [91, 92]. As IFN-𝛾 produc-
ers, NK cells might significantly enhance PD-L1 expression
on tumor cells. In this context it has been recently shown
that supernatants conditioned by IL-2-activated NK cells
could increase PD-L1 expression on hematopoietic tumor cell
lines and primary Multiple Myeloma (MM), Acute Myeloid
Leukemia (AML), andAcute Lymphoblastic Leukemia (ALL)
cancer cells [93]. Interestingly, in lung cancer, a recent report
showed an important correlation between PD-L1 expression
and EMT score [94].
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A role for NK cells in the modulation of tumor cell
phenotype may be particularly significant in the context of
tumor cells that express very low levels of HLA-I and cannot
efficiently stimulate T cells. Neuroblastoma cells often show
low or negative HLA-I surface expression [95, 96]; in this
case, the adaptive immune resistance/immunoeditingmay be
driven by NK cells rather than T cells. However, in spite of
the lack of HLA-I expression, neuroblasts isolated from bone
marrow aspirates have been shown to be quite resistant to NK
cell-mediated killing. This resistance was associated with the
lack of ligands for activating receptors (i.e., PVR, recognized
by DNAM-1) or with the high expression of B7-H3, a ligand
for a still unknown inhibitory NK receptor [96]. Thus, these
metastatic neuroblasts may hardly stimulate both T and NK
cells, which may result in a lack of IFN-𝛾 production. This
situation may account for the recent observation that such
aggressive neuroblasts do not constitutively express PD-L1
[97]. Along this line, it has been recently shown that, indeed,
metastatic neuroblasts can significantly acquire PD-L1 (and
HLA-I) expression in response to IFN-𝛾 [97].
To conclude this issue, it should be considered that an
actual evaluation of the possible effects of NK cells on the
tumor cell phenotype and plasticity cannot disregard the
effective location of the NK infiltrate in the tumor tissue.
3. Infiltration of NK Cells in Solid Tumors
The study of the NK cell infiltrate in solid tumors has been
made possible only recently, thanks to the generation of new
reagents for the specific detection of NK cells by immuno-
histochemistry and the availability of even more efficient
approaches to isolate and/or analyze specific lymphocyte
populations from tissues.
TheNK cell infiltrate has been assessed in several types of
solid tumors including melanomas [89, 98], GastroIntestinal
Stromal Tumors (GIST) [47], and colorectal [99], renal [44],
lung [100], and breast cancers [45] (Table 1).
In some cases a role for infiltrating NK cells in the control
of tumor progression could be also inferred. Two studies on
renal carcinoma lung metastases and GIST found a correla-
tion between the levels of the NK infiltrate and better prog-
nosis [37, 44]. Another interesting study on GIST showed
that the number ofNKp46+ TILs inversely correlatedwith the
presence of metastases at diagnosis and indicated that differ-
ent isoforms of the NKp30 activating receptor could associate
with reduced or prolonged survival of the patients [46].
Ali and colleagues have also recently shown that tumor-
infiltrated LN of melanoma patients are enriched in highly
cytotoxic CD56dimCD57+KIR+ NK cells (instead of the
poorly cytotoxic CD56bright NK cells which are typically
located in LN) [41]. In this context, it should be considered
that the cytotoxic activity of the NK cell pool can significantly
vary among individuals and that low PB NK cell activity has
been associated in the past with an increased risk of many
cancers [22, 101].
On the other hand, several data available in the literature
call into question the real effect of NK cells on the progression
of the tumor. Some studies indicate a scarce or moderate NK
cell infiltration in melanomas, colon cancers, and tumor tis-
sues microarray [42, 89, 102]. In addition, studies addressing
the phenotype and function of tumor-infiltrating NK cells
have shown an enrichment of poorly cytotoxic CD56bright NK
cells (in lung and breast tumor tissues) or the presence of
altered poorly functionalCD56dimNKcells in different tumor
types (see Table 1). Finally, independent studies on colorectal
cancer, melanoma, and GIST have shown that NK cells may
be preferentially located in the stroma, rather than in direct
contact with tumor cells [23].
Overall, these conflicting data point out the still open
question on how NK cell recruitment and migration are
specifically regulated within the tumor tissue. As generally
conceived, the migration process would depend on cell-
to-cell and cell-to-extracellular matrix (ECM) interactions,
modulation of ECM components, the presence of spe-
cific chemokines, and the pattern of chemokine receptors
expressed by various NK cell types [103].
The chemokine receptor patterns of the most studied PB
NK cell subsets (i.e., the CD56bright cells and the composite
group of the CD56dim cells) have been roughly defined,
although some published studies are not concordant with
regard to the expression of certain specific receptors. Such
discrepancies may depend on the sensitivity of the antibodies
used for flow cytometric analysis or on the use of different cell
isolation techniques (whichmay alter the chemokine receptor
recognition by the specific reagent) [104, 105].
Well-established data indicate that the CD56dimCD16+
cells express CXCR1, ChemR23, and CX
3
CR1 at high levels
and respond to CXCL8 and CX
3
CL1 [106]. Accordingly, these
cells may cross the endothelium and reach inflamed tissues or
tumor masses (as chronic inflammation often characterizes
tumor microenvironment). Moreover, CD56dimCD16+ cells
also express low levels of CXCR2 and CXCR3 but lack CCR7
and CXCR5. By contrast, CD56brightCD16− cells express
high levels of CCR7 and CXCR3 suggesting that this cell
subset would migrate in response to CCL19, CCL21, CXCL9,
CXCL10, and CXCL11. CD56brightCD16− cells also express
low levels of CX
3
CR1 and lack CXCR1, CXCR2, and CXCR5
[15, 104, 105, 107, 108]. Such chemokine receptor pattern is
consistent with the prevalent localization of CD56bright cells
in LN, but also with the recent observation that an infiltration
of CD56bright cells can be detected in tumors showing high
CCL19, CCL21, and CXCL9 transcripts [35].
It should be also considered that NK cells can modify the
expression of chemokines and chemokine receptors following
cytokine stimulation. For example, short term stimulation
of NK cells with IL-2 and/or IL-12 results in a decreased
expression of CXCR3 [109], while long term exposure to IL-
2 upregulates CCR1, CCR2, CCR4, CCR5, and CCR8 and
downregulates the expression of CXCR2 and ChemR23 [110].
In addition, IL-2 can also modulate the expression of CCR7
and induce CCR4 and CX3CR1 expression. IL-15 stimulation
causes a decrease of CXCR4 andCX3CR1 expression [111]; IL-
18 enhances the response to CCL21 through the induction of
CCR7 [112]; TGF-𝛽 induces CXCR3 and CXCR4 expression
while deeply reducing CX
3
CR1 surface levels [25]. Therefore,
the composition and the localization of the NK cell infiltrate
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would greatly vary, depending on the type of cytokines
and chemokines available in the tumor. In mice, using NK
cell-sensitive tumor models, it has been shown that IFN-
𝛾 can induce the release of CXCL9-10 by tumor-infiltrating
immune cells leading to the recruitment of CXCR3+ NK cells
[113]. In another study on mice it has been shown that the
chemoattractant molecule chemerin can favor the recruit-
ment of NK cells in B16 transplantable melanomas [114].
Interestingly, in humans, the expression of the gene coding
for chemerin was downregulated in several tumor types [115].
In a recent study, comparing PBNK cells fromhealthy donors
and neuroblastoma patients it has been shown that patients’
CD56dim NK cells display a significantly reduced expression
of CX
3
CR1, a chemokine receptor involved in the process
of cell extravasation [25]. In another study Halama and
colleagues have shown a scarce NK cell infiltrate in col-
orectal cancers despite the high levels of NK cell-attracting
chemokines within the tumor. These findings indicate that
tumor-orchestrated escape mechanisms may affect NK cell
viability in the tumor niche or inhibit the recruitment of
NK cells at the tumor site, but also suggest that, besides
chemokines, additional chemoattractant molecules may be
necessary for the recruitment [42]. Along this line, the role of
HMGB1 as chemoattractant for NK cells in tumors has been
recently highlighted (see below). Actually, this pleiotropic
molecule has recently come into play in various aspects of the
tumor biology, not least EMT.
4. HMGB1, Immune Cells, and Tumors
HMGB1 is a widely expressed protein mainly localized in the
cell nucleus and involved in chromatin remodeling and tran-
scription [116]. However, following cell activation by various
physiopathological stimuli, this protein can undergo post-
translational modifications that promote its translocation to
the cytosol and its export outside the cell, via a nonclassic
secretion pathway that requires LAMP1 positive lysosomes
[117]. HMGB1 can also undergo a passive release from dam-
aged or necrotic cells and behaves as a Damage Associated
Molecular Pattern (DAMP) able to trigger and amplify both
inflammatory and immune responses [118, 119]. Autophagy
induction is required and sufficient to cause the release of
HMGB1 from dying cells, suggesting that manipulation
of autophagy during cancer treatment may influence the
immunogenicity of dying tumor cells [120]. Furthermore,
HMGB1 has been identified as a cytokine-releasing factor that
stimulates the production of TNF-𝛼, IL-1𝛽, IL-6, and IL-8
from macrophages and neutrophils [121].
The signaling properties of HMGB1 are influenced by
the redox state of its cysteine residues localized at positions
23, 45, and 106 [122]. At this respect, all-thiol (i.e., fully
reduced) HMGB1 interacts with CXCL12 and the heterocom-
plex behaves as a chemoattractant for mouse macrophages
and fibroblasts and for humanmonocytes by the engagement
of CXCR4 [123–125]. Moreover, HMGB1 can also induce
chemotaxis of human monocyte-derived immature DCs
through the engagement of RAGE [126]. Conversely, a par-
tial and reversible oxidation of HMGB1 (C23-C45 disulfide
bond) is required to activate a TLR4-mediated production of
cytokines frommacrophages [127]. Instead, HMGB1 released
from apoptotic cells is characterized by the irreversible oxi-
dation of C106 to sulfonic acid by ROS. In this oxidation state
HMGB1 lacks cytokine-inducing activity, induces tolerogenic
DCs, and promotes cell death following treatment with
chemotherapeutic agents [128, 129]. Finally, a fully oxidized
HMGB1 form has been also described, but its functions have
not been yet assessed.
In addition to the redox status, several posttranslational
modifications may be relevant to HMGB1 function. So far,
the identified modifications on HMGB1 molecules exported
from innate immune cells consist of hyperacetylation [130,
131], poly-ADP ribosylation [132], and phosphorylation by
CAMK IV and PKC [133–136]. The effects of these molecular
changes on the affinity of HMGB1 for its different receptors
and their role in cell responses in solid tumors have not been
yet explored.
Finally, it should also be considered that HMGB1 can
associate with various soluble HMGB1-binding molecules,
such as IL-1𝛽, LPS, Pam(3)Csk(4), and the above-mentioned
CXCL12, and enhance their immunostimulatory activity [137,
138].
Due to its molecular plasticity, HMGB1, either alone or
complexed with other molecules, can interact with several
receptors including RAGE, IL-1R, TLR2, TLR4, CXCR4,
NMDA-R, and TIM-3 [137–141].
Several different stimuli are able to trigger the release of
HMGB1 from cells of the innate immune system. In partic-
ular, an active export of HMGB1 is induced on monocytes,
macrophages, and DCs activated by PAMPs, DAMPs, or
cytokines. In addition, also NK cells can actively release
HMGB1 in the context of the NK:DC cross talk or upon the
engagement of different activating NK cell receptors, includ-
ing those mainly involved in tumor cell recognition [130,
142–144]. On the other hand, neutrophils mostly undergo a
passive release ofHMGB1 following cell injury/necrosis [145],
whereas, to our knowledge, no information on the export of
HMGB1 from eosinophils and basophils is available. Besides
innate immune cells, endothelial cells and fibroblasts can also
actively release HMGB1 following the exposure to uric acid
and LPS, respectively [146, 147]. It should be also noted that
several innate immune cells are targets of HMGB1. In partic-
ular, on monocyte-derived immature DCs, HMGB1 upreg-
ulates specific maturation markers (CD80, CD83, CD86,
and HLA-I), enhances the production of cytokines (IL-6,
CXCL8, IL-12 p70, and TNF-𝛼), switches their chemokine
responsiveness from CCL5-sensitive to CCL21-sensitive, and
induces the cell capacity to stimulate allogeneic T cell prolifer-
ation [126].Moreover, HMGB1 released fromprimary tumors
can reach the regional LN and weaken their antimetastatic
capability by lowering the number of resident macrophages
[148]. Depending on its concentration,HMGB1 can induce or
inhibit neutrophil chemotactic responses by the engagement
of RAGE,TLR2, andTLR4 [149].The essential role ofHMGB1
as a crucial modulator of innate immunity in tumors is sup-
ported by in vivo evidences showing that HMGB1-deficient
tumors display an impaired ability to recruit innate immune
cells, including macrophages, neutrophils, and NK cells into
the tumor tissue following DNA alkylating therapy [150].
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Figure 1: New mechanism proposed for NK cell recruitment at melanoma tumor site. NK cells recognize melanoma cells through the
interaction of NK activating receptors with their ligands (NKR-Ls) expressed on tumor cell (both depicted in dark blue). The resulting NK
cell activation leads to the killing of melanoma cells (via perforin/granzyme B and induction of apoptosis) and to the active release of a
chemotactic form of HMGB1 (green circles). Killed (apoptotic) cells passively release HMGB1 as oxidized molecule. However, this HMGB1
form has no chemotactic properties (purple circles). NK-derived reduced (i.e., all-thiol) HMGB1 can act as chemoattractant for activated NK
cells through the engagement of RAGE (depicted in green), thus promoting their recruitment in the tumor microenvironment.
The intracellular amount of HMGB1 is significantly
increased in several human tumors such as lung [151], bladder
[152], colorectal [153], head and neck [154], prostate [155],
hepatocellular [156], and gastric cancer [157] and melanoma
[158]. This observation suggests that tumor cells can release
high amounts of HMGB1 either by membrane leakage or
by active release in inflammatory or hypoxic conditions that
are often observed in solid tumors and associated with an
increased prometastatic behavior [159]. ExtracellularHMGB1
can play further roles in cancer through the activation of
endothelial cells. Specifically, the all-thiol form displays a
proangiogenic activity that supports tumor growth [160, 161].
The heterogeneous responses observed in different condi-
tions could depend on the local concentration of the different
redox forms of the protein, on the type of cellular receptors
engaged by HMGB1, and on the presence of specific sol-
uble HMGB1-binding molecules [137, 138]. Thus, HMGB1
from both tumor and immune cells can accumulate in
the tumor microenvironment and sustain inflammation,
cytokine release, cell proliferation, and recruitment of
immune cells. The full characterization of these effects and
the evaluation of their importance in the context of the tumor
development (or control)may be crucial for the identification
of new checkpoints in the host:tumor interaction and for the
definition of effective therapeutic targets. In this context we
have recently described a new mechanism by which HMGB1
could strongly influence the presence and the efficacy of NK
cells at the tumor site.
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4.1. Role of HMGB1 in NK Cell-Tumor Interaction. We have
recently addressed the role of HMGB1 in the context of the
innate immune response against tumors by investigating the
function of this protein in the NK:melanoma cell interaction
and in the subsequent NK-mediated killing of tumor cells.
We have shown that, during the interaction with melanoma
cells, NK cells could release an HMGB1 form endowed
with chemotactic activity, while killed melanoma cells pas-
sively released an oxidized, nonchemotactic form of HMGB1
(Figure 1). The chemotactic HMGB1 could potently attract
activated NK cells through the engagement of RAGE, which,
indeed, was expressed at the surface of NK cells. Interestingly,
after prolonged exposure to HMGB1, NK cells did not
enhance their chemotactic properties; rather, they showed an
increased cell motility, whichwas accompanied by expression
changes in several proteins involved in the regulation of the
cytoskeletal network [144]. Thus, our finding defined a new
mechanism by which HMGB1 could sustain the antitumor
function of NK cells. Indeed, HMGB1 could initially play
a crucial role in amplifying the NK cell recruitment to the
site of NK:tumor cell interaction; next, it could improve the
patrolling capability of NK cells that have reached the tumor
by enhancing their motility.
The presence of HMGB1 in the context of the NK:tumor
cell interaction may also play a role in the progression of the
tumor. Recent observations show that HMGB1 is a potent
driver of EMT in colorectal carcinoma via the activation of
the RAGE/Snail/NF-𝜅B pathway and of MMP-7 [53]. NK
cells have been shown to be frequently located in the front
of invasion of the tumor, where, indeed, the EMT process
is likely to occur. Thus, in this situation, HMGB1 may recall
additional NK cells in the area, which, in turn, would release
further HMGB1 thus contributing to the EMT.
It is worth noting that NK cells also express TIM-3,
which has been shown to recognize HMGB1 [162]. Moreover,
HMGB1 may also influence NK cell function by its ability to
potentiate the activity of the NMDA receptor [141]. Indeed,
the activation of this protein channel in human NK cells, T
lymphocytes, and neutrophils has been shown to increase the
production of ROS [163]. These receptors do not appear to
modulate HMGB1-mediated NK chemotaxis, but their possi-
ble involvement in additional functions cannot be ruled out.
5. Concluding Remarks
While several reports demonstrate the inefficacy of NK cells
in controlling tumor growth and invasion, NK cell role in
the prevention of metastasis has been described in different
types of cancer, and a higher number of tumor-infiltratingNK
cells have been associated with a better prognosis [20–24].
Thus, it is not surprising that in the past years these ILCs have
starred in cancer immunotherapy clinical trials with promis-
ing results. Therefore, it could be unpopular to ask about
their potential role in the tumor progression. Nonetheless,
during antitumor immune responses, NK cells can represent
a source of IFN-𝛾, which potentially promotes the adaptive
immune resistance of tumor cells, and TNF-𝛼, a known
EMT inducer. In addition, NK cells may be often located
within the stroma, at the interface with the invasive front of
the tumor, where, indeed, the EMT (i.e., the transitional
tumor cell phenotype) is frequently observed. Thus several
hints foster the idea that NK cells, in spite of their potential
ability to control metastases, may also play an unwanted role
in the promotion of cancer plasticity. This controversial issue
should be definitively clarified.The definition of whether and
how NK cells are recruited, migrate within the tumor, and
influence the EMT, along with the new insights into the puta-
tive role of HMGB1, would provide new important elements
to maximize the still unexplored potential of NK cells in the
therapy of solid tumors.
Competing Interests
Alessandro Moretta is a founder and shareholder of Innate-
Pharma (Marseille, France) and Daniel Olive is cofounder
of Imcheck Therapeutics (Marseille, France). The remaining
authors declare no competing interests.
Acknowledgments
This work was supported by grants awarded by AIRC: IG
Project no. 15428 (Massimo Vitale); 5x1000 Min. Sal. 2011
and 2013 (Maria Cristina Mingari and Massimo Vitale);
AIRC: IG Project no. 15704 and Special Project 5x1000 9962
(Alessandro Moretta, Cristina Bottino, and Roberta Castri-
coni). Monica Parodi is recipient of the AIRC Fellowship no.
18274, year 2016.
References
[1] H. Spits, D. Artis, M. Colonna et al., “Innate lymphoid cells—a
proposal for uniform nomenclature,”Nature Reviews Immunol-
ogy, vol. 13, no. 2, pp. 145–149, 2013.
[2] E. Montaldo, P. Vacca, L. Moretta, and M. C. Mingari, “Devel-
opment of human natural killer cells and other innate lymphoid
cells,” Seminars in Immunology, vol. 26, no. 2, pp. 107–113, 2014.
[3] E. Vivier, D. H. Raulet, A. Moretta et al., “Innate or adaptive
immunity?The example of natural killer cells,” Science, vol. 331,
no. 6013, pp. 44–49, 2011.
[4] E. Montaldo, P. Vacca, C. Vitale et al., “Human innate lymphoid
cells,” Immunology Letters, 2016.
[5] A. Cerwenka and L. L. Lanier, “Natural killer cell memory in
infection, inflammation and cancer,” Nature Reviews Immunol-
ogy, vol. 16, no. 2, pp. 112–123, 2016.
[6] L. Moretta, C. Bottino, D. Pende, M. Vitale, M. C. Mingari, and
A. Moretta, “Different checkpoints in human NK-cell activa-
tion,” Trends in Immunology, vol. 25, no. 12, pp. 670–676, 2004.
[7] C. Fauriat, E. O. Long, H.-G. Ljunggren, and Y. T. Bryceson,
“Regulation of human NK-cell cytokine and chemokine pro-
duction by target cell recognition,” Blood, vol. 115, no. 11, pp.
2167–2176, 2010.
[8] A.Moretta, E.Marcenaro, S. Sivori,M. D. Chiesa,M. Vitale, and
L. Moretta, “Early liaisons between cells of the innate immune
system in inflamed peripheral tissues,” Trends in Immunology,
vol. 26, no. 12, pp. 668–675, 2005.
[9] F. Bellora, R. Castriconi, A. Dondero et al., “TLR activation
of tumor-associated macrophages from ovarian cancer patients
triggers cytolytic activity of NK cells,” European Journal of
Immunology, vol. 44, no. 6, pp. 1814–1822, 2014.
Journal of Immunology Research 9
[10] F. B. Thore´n, R. E. Riise, J. Ousba¨ck et al., “Human NK cells
induce neutrophil apoptosis via an NKp46- and Fas-dependent
mechanism,” The Journal of Immunology, vol. 188, no. 4, pp.
1668–1674, 2012.
[11] A. Mart´ın-Fontecha, L. L. Thomsen, S. Brett et al., “Induced
recruitment of NK cells to lymph nodes provides IFN-𝛾 for
TH1 priming,”Nature Immunology, vol. 5, no. 12, pp. 1260–1265,
2004.
[12] F. Ghiringhelli, C. Me´nard, F. Martin, and L. Zitvogel, “The role
of regulatory T cells in the control of natural killer cells: rele-
vance during tumor progression,” Immunological Reviews, vol.
214, no. 1, pp. 229–238, 2006.
[13] S. Sivori, M. Falco, M. Della Chiesa et al., “CpG and double-
stranded RNA trigger human NK cells by toll-like receptors:
induction of cytokine release and cytotoxicity against tumors
dendritic cells,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 101, no. 27, pp. 10116–10121,
2004.
[14] S. Sivori, S. Carlomagno, S. Pesce, A. Moretta, M. Vitale, and
E. Marcenaro, “TLR/NCR/KIR: which one to use and when?”
Frontiers in Immunology, vol. 5, article 105, 2014.
[15] M. A. Cooper, T. A. Fehniger, andM. A. Caligiuri, “The biology
of human natural killer-cell subsets,”Trends in Immunology, vol.
22, no. 11, pp. 633–640, 2001.
[16] N. K. Bjo¨rkstro¨m, P. Riese, F. Heuts et al., “Expression patterns
of NKG2A, KIR, and CD57 define a process of CD56 dim NK-
cell differentiation uncoupled from NK-cell education,” Blood,
vol. 116, no. 19, pp. 3853–3864, 2010.
[17] S. Lopez-Verge`s, J. M. Milush, S. Pandey et al., “CD57 defines
a functionally distinct population of mature NK cells in the
human CD56dimCD16+ NK-cell subset,” Blood, vol. 116, no. 19,
pp. 3865–3874, 2010.
[18] L. Moretta, “Dissecting CD56dim human NK cells,” Blood, vol.
116, no. 19, pp. 3689–3691, 2010.
[19] T. Pradeu, S. Jaeger, and E. Vivier, “The speed of change:
towards a discontinuity theory of immunity?” Nature Reviews
Immunology, vol. 13, no. 10, pp. 764–769, 2013.
[20] S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M.
Yokoyama, “In vivo natural killer cell activities revealed by
natural killer cell-deficient mice,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 97, no.
6, pp. 2731–2736, 2000.
[21] T. Lakshmikanth, S. Burke, T. H. Ali et al., “NCRs and DNAM-
1 mediate NK cell recognition and lysis of human and mouse
melanoma cell lines in vitro and in vivo,”The Journal of Clinical
Investigation, vol. 119, no. 5, pp. 1251–1263, 2009.
[22] K. Imai, S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi,
“Natural cytotoxic activity of peripheral-blood lymphocytes
and cancer incidence: an 11-year follow-up study of a general
population,”The Lancet, vol. 356, no. 9244, pp. 1795–1799, 2000.
[23] A. Stojanovic and A. Cerwenka, “Natural killer cells and solid
tumors,” Journal of Innate Immunity, vol. 3, no. 4, pp. 355–364,
2011.
[24] M. Vitale, C. Cantoni, G. Pietra, M. C. Mingari, and L. Moretta,
“Effect of tumor cells and tumor microenvironment on NK-cell
function,” European Journal of Immunology, vol. 44, no. 6, pp.
1582–1592, 2014.
[25] R. Castriconi, A. Dondero, F. Bellora et al., “Neuroblastoma-
derived TGF-𝛽1 modulates the chemokine receptor repertoire
of human resting NK cells,” Journal of Immunology, vol. 190, no.
10, pp. 5321–5328, 2013.
[26] M. Della Chiesa, S. Carlomagno, G. Frumento et al., “The tryp-
tophan catabolite L-kynurenine inhibits the surface expression
of NKp46- and NKG2D-activating receptors and regulates NK-
cell function,” Blood, vol. 108, no. 13, pp. 4118–4125, 2006.
[27] E. Schlecker, N. Fiegler, A. Arnold et al., “Metalloprotease-
mediated tumor cell shedding of B7-H6, the ligand of the natu-
ral killer cell-activating receptor NKp30,” Cancer Research, vol.
74, no. 13, pp. 3429–3440, 2014.
[28] R. Castriconi, C. Cantoni, M. D. Chiesa et al., “Transforming
growth factor 𝛽1 inhibits expression of NKP30 and NKG2d
receptors: consequences for the NK-mediated killing of den-
dritic cells,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 100, no. 7, pp. 4120–4125, 2003.
[29] B.Hoechst, T. Voigtlaender, L.Ormandy et al., “Myeloid derived
suppressor cells inhibit natural killer cells in patients with
hepatocellular carcinoma via the NKp30 receptor,” Hepatology,
vol. 50, no. 3, pp. 799–807, 2009.
[30] M. F. Sprinzl, F. Reisinger, A. Puschnik et al., “Sorafenib per-
petuates cellular anticancer effector functions by modulating
the crosstalk between macrophages and natural killer cells,”
Hepatology, vol. 57, no. 6, pp. 2358–2368, 2013.
[31] M. Balsamo, F. Scordamaglia, G. Pietra et al., “Melanoma-
associated fibroblasts modulate NK cell phenotype and anti-
tumor cytotoxicity,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 106, no. 49, pp.
20847–20852, 2009.
[32] G. Pietra, C. Manzini, S. Rivara et al., “Melanoma cells inhibit
natural killer cell function by modulating the expression of
activating receptors and cytolytic activity,”Cancer Research, vol.
72, no. 6, pp. 1407–1415, 2012.
[33] C. Pasero, G. W. Gravis, M. Guerin et al., “Inherent and tumor-
driven immune tolerance in the prostate microenvironment
impairs natural killer cell antitumor activity,” Cancer Research,
vol. 76, no. 8, pp. 2153–2165, 2016.
[34] B. Le Maux Chansac, A. Moretta, I. Vergnon et al., “NK
cells infiltrating a MHC class I-deficient lung adenocarcinoma
display impaired cytotoxic activity toward autologous tumor
cells associated with altered NK Cell-triggering receptors,”The
Journal of Immunology, vol. 175, no. 9, pp. 5790–5798, 2005.
[35] P. Carrega, I. Bonaccorsi, E. Di Carlo et al.,
“CD56brightperforinlow noncytotoxic human NK cells are abun-
dant in both healthy and neoplastic solid tissues and recirculate
to secondary lymphoid organs via afferent lymph,”The Journal
of Immunology, vol. 192, no. 8, pp. 3805–3815, 2014.
[36] P. Carrega, B. Morandi, R. Costa et al., “Natural killer cells
infiltrating human nonsmall-cell lung cancer are enriched in
CD56 bright CD16(−) cells and display an impaired capability
to kill tumor cells,” Cancer, vol. 112, no. 4, pp. 863–875, 2008.
[37] S. Platonova, J. Cherfils-Vicini, D. Damotte et al., “Profound
coordinated alterations of intratumoral NK cell phenotype and
function in lung carcinoma,”Cancer Research, vol. 71, no. 16, pp.
5412–5422, 2011.
[38] C. S. Vetter, V. Groh, P.Thor Straten, T. Spies, E.-B. Bro¨cker, and
J. C. Becker, “Expression of stress-induced MHC class I related
chain molecules on human melanoma,” Journal of Investigative
Dermatology, vol. 118, no. 4, pp. 600–605, 2002.
[39] G. Erdag, J. T. Schaefer, M. E. Smolkin et al., “Immuno-
type and immunohistologic characteristics of tumor-infiltrating
immune cells are associated with clinical outcome in metastatic
melanoma,” Cancer Research, vol. 72, no. 5, pp. 1070–1080, 2012.
[40] M. Messaoudene, G. Fregni, E. Fourmentraux-Neves et al.,
“Mature cytotoxic CD56𝑏𝑟𝑖𝑔ℎ𝑡/CD16+ natural killer cells can
10 Journal of Immunology Research
infiltrate lymph nodes adjacent to metastatic melanoma,” Can-
cer Research, vol. 74, no. 1, pp. 81–92, 2014.
[41] T. H. Ali, S. Pisanti, E. Ciaglia et al., “Enrichment of
CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-
infiltrated lymph nodes ofmelanoma patients,”Nature Commu-
nications, vol. 5, article 5639, 2014.
[42] N. Halama, M. Braun, C. Kahlert et al., “Natural killer cells
are scarce in colorectal carcinoma tissue despite high levels of
chemokines and cytokines,”Clinical Cancer Research, vol. 17, no.
4, pp. 678–689, 2011.
[43] Y. S. Rocca, M. P. Roberti, J. M. Arriaga et al., “Altered pheno-
type in peripheral blood and tumor-associated NK cells from
colorectal cancer patients,” Innate Immunity, vol. 19, no. 1, pp.
76–85, 2013.
[44] R. Remark, M. Alifano, I. Cremer et al., “Characteristics and
clinical impacts of the immune environments in colorectal and
renal cell carcinoma lungmetastases: influence of tumor origin,”
Clinical Cancer Research, vol. 19, no. 15, pp. 4079–4091, 2013.
[45] E. Mamessier, A. Sylvain, M.-L. Thibult et al., “Human breast
cancer cells enhance self tolerance by promoting evasion from
NK cell antitumor immunity,” Journal of Clinical Investigation,
vol. 121, no. 9, pp. 3609–3622, 2011.
[46] N. F. Delahaye, S. Rusakiewicz, I. Martins et al., “Alternatively
spliced NKp30 isoforms affect the prognosis of gastrointestinal
stromal tumors,” Nature Medicine, vol. 17, no. 6, pp. 700–707,
2011.
[47] S. Rusakiewicz, M. Semeraro, M. Sarabi et al., “Immune infil-
trates are prognostic factors in localized gastrointestinal stromal
tumors,” Cancer Research, vol. 73, no. 12, pp. 3499–3510, 2013.
[48] J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto,
“Epithelial-mesenchymal transitions in development and dis-
ease,” Cell, vol. 139, no. 5, pp. 871–890, 2009.
[49] K. Polyak and R. A. Weinberg, “Transitions between epithelial
and mesenchymal states: acquisition of malignant and stem cell
traits,” Nature Reviews Cancer, vol. 9, no. 4, pp. 265–273, 2009.
[50] K. Kemper, P. L. de Goeje, D. S. Peeper, and R. van Amerongen,
“Phenotype switching: tumor cell plasticity as a resistance
mechanism and target for therapy,” Cancer Research, vol. 74, no.
21, pp. 5937–5941, 2014.
[51] M. Balsamo, C. Manzini, G. Pietra et al., “Hypoxia downregu-
lates the expression of activating receptors involved in NK-cell-
mediated target cell killing without affecting ADCC,” European
Journal of Immunology, vol. 43, no. 10, pp. 2756–2764, 2013.
[52] R. Kang, Q. Zhang, H. J. Zeh III, M. T. Lotze, and D. Tang,
“HMGB1 in cancer: good, bad, or both?” Clinical Cancer
Research, vol. 19, no. 15, pp. 4046–4057, 2013.
[53] L. Zhu, X. Li, Y. Chen, J. Fang, and Z. Ge, “High-mobility group
Box 1: a novel inducer of the epithelial-mesenchymal transition
in colorectal carcinoma,” Cancer Letters, vol. 357, no. 2, pp. 527–
534, 2015.
[54] C. E. Meacham and S. J. Morrison, “Tumour heterogeneity and
cancer cell plasticity,” Nature, vol. 501, no. 7467, pp. 328–337,
2013.
[55] J. H. Tsai and J. Yang, “Epithelial-mesenchymal plasticity in
carcinoma metastasis,” Genes and Development, vol. 27, no. 20,
pp. 2192–2206, 2013.
[56] J. P. Thiery and J. P. Sleeman, “Complex networks orchestrate
epithelial-mesenchymal transitions,” Nature Reviews Molecular
Cell Biology, vol. 7, no. 2, pp. 131–142, 2006.
[57] E. Pirila¨, N. S. Ramamurthy, T. Sorsa, T. Salo, J. Hietanen, and
P. Maisi, “Gelatinase A (MMP-2), collagenase-2 (MMP-8), and
laminin-5 𝛾2-chain expression in murine inflammatory bowel
disease (ulcerative colitis),” Digestive Diseases and Sciences, vol.
48, no. 1, pp. 93–98, 2003.
[58] G. Giannelli, C. Bergamini, E. Fransvea, C. Sgarra, and S.
Antonaci, “Laminin-5 with transforming growth factor-𝛽1
induces epithelial to mesenchymal transition in hepatocellular
carcinoma,” Gastroenterology, vol. 129, no. 5, pp. 1375–1383,
2005.
[59] K. Cheng, G. Xie, and J.-P. Raufman, “Matrix metalloprotein-
ase-7-catalyzed release of HB-EGF mediates deoxycholyltau-
rine-induced proliferation of a human colon cancer cell line,”
Biochemical Pharmacology, vol. 73, no. 7, pp. 1001–1012, 2007.
[60] B. De Craene and G. Berx, “Regulatory networks defining
EMT during cancer initiation and progression,”Nature Reviews
Cancer, vol. 13, no. 2, pp. 97–110, 2013.
[61] A. Cano, M. A. Pe´rez-Moreno, I. Rodrigo et al., “The transcrip-
tion factor Snail controls epithelial-mesenchymal transitions by
repressing E-cadherin expression,” Nature Cell Biology, vol. 2,
no. 2, pp. 76–83, 2000.
[62] J. Comijn, G. Berx, P. Vermassen et al., “The two-handed E box
binding zinc finger protein SIP1 downregulates E-cadherin and
induces invasion,” Molecular Cell, vol. 7, no. 6, pp. 1267–1278,
2001.
[63] K. M. Hajra, David Y-S. Chen, and E. R. Fearon, “The SLUG
zinc-finger protein represses E-cadherin in breast cancer,”
Cancer Research, vol. 62, no. 6, pp. 1613–1618, 2002.
[64] V. Bolo´s, H. Peinado, M. A. Pe´rez-Moreno, M. F. Fraga, M.
Esteller, and A. Cano, “The transcription factor Slug represses
E-cadherin expression and induces epithelial to mesenchymal
transitions: a comparison with Snail and E47 repressors,”
Journal of Cell Science, vol. 116, part 3, pp. 499–511, 2003.
[65] J. Yang, S. A.Mani, J. L.Donaher et al., “Twist, amaster regulator
of morphogenesis, plays an essential role in tumor metastasis,”
Cell, vol. 117, no. 7, pp. 927–939, 2004.
[66] P. A. Gregory, A. G. Bert, E. L. Paterson et al., “The miR-200
family and miR-205 regulate epithelial to mesenchymal transi-
tion by targeting ZEB1 and SIP1,”Nature Cell Biology, vol. 10, no.
5, pp. 593–601, 2008.
[67] N. R. Christoffersen, A. Silahtaroglu, U. A.Ørom, S. Kauppinen,
and A. H. Lund, “miR-200b mediates post-transcriptional
repression of ZFHX1B,” RNA, vol. 13, no. 8, pp. 1172–1178, 2007.
[68] K. S. Hoek, O.M. Eichhoff, N. C. Schlegel et al., “In vivo switch-
ing of humanmelanoma cells between proliferative and invasive
states,” Cancer Research, vol. 68, no. 3, pp. 650–656, 2008.
[69] M. Sa´ez-Ayala, M. F. Montenegro, L. Sa´nchez-del-Campo et al.,
“Directed phenotype switching as an effective antimelanoma
strategy,” Cancer Cell, vol. 24, no. 1, pp. 105–119, 2013.
[70] S. Huang,M.Ho¨lzel, T. Knijnenburg et al., “MED12 controls the
response to multiple cancer drugs through regulation of TGF-𝛽
receptor signaling,” Cell, vol. 151, no. 5, pp. 937–950, 2012.
[71] F. Z. Li, A. S. Dhillon, R. L. Anderson, G. McArthur, and P.
T. Ferrao, “Phenotype switching in melanoma: implications for
progression and therapy,” Frontiers in Oncology, vol. 5, article 31,
2015.
[72] G. P. Dunn, L. J. Old, and R. D. Schreiber, “The three Es of
cancer immunoediting,”Annual Review of Immunology, vol. 22,
pp. 329–360, 2004.
[73] M. J. Smyth, “NK cells and NKT cells collaborate in host
protection from methylcholanthrene-induced fibrosarcoma,”
International Immunology, vol. 20, no. 4, p. 631, 2008.
Journal of Immunology Research 11
[74] M. J. Smyth, N. Y. Crowe, and D. I. Godfrey, “NK cells and NKT
cells collaborate in host protection from methylcholanthrene-
induced fibrosarcoma,” International Immunology, vol. 13, no.
4, pp. 459–463, 2001.
[75] M. Girardi, D. E. Oppenheim, C. R. Steele et al., “Regulation of
cutaneous malignancy by 𝛾𝛿 T cells,” Science, vol. 294, no. 5542,
pp. 605–609, 2001.
[76] D. Hanahan and L. M. Coussens, “Accessories to the crime:
functions of cells recruited to the tumor microenvironment,”
Cancer Cell, vol. 21, no. 3, pp. 309–322, 2012.
[77] C.-Y. Liu, J.-Y. Xu, X.-Y. Shi et al., “M2-polarized tumor-
associated macrophages promoted epithelial-mesenchymal
transition in pancreatic cancer cells, partially through TLR4/IL-
10 signaling pathway,” Laboratory Investigation, vol. 93, no. 7,
pp. 844–854, 2013.
[78] D. Marvel and D. I. Gabrilovich, “Myeloid-derived suppressor
cells in the tumor microenvironment: expect the unexpected,”
Journal of Clinical Investigation, vol. 125, no. 9, pp. 3356–3364,
2015.
[79] K. Oguma, H. Oshima, M. Aoki et al., “Activated macrophages
promote Wnt signalling through tumour necrosis factor-𝛼 in
gastric tumour cells,”TheEMBO Journal, vol. 27, no. 12, pp. 1671–
1681, 2008.
[80] B. Toh, X. Wang, J. Keeble et al., “Mesenchymal transition
and dissemination of cancer cells is driven by myeloid-derived
suppressor cells infiltrating the primary tumor,” PLoS Biology,
vol. 9, no. 9, Article ID e1001162, 2011.
[81] C. Kudo-Saito, H. Shirako, T. Takeuchi, and Y. Kawakami,
“Cancer metastasis is accelerated through immunosuppression
during snail-induced EMT of cancer cells,” Cancer Cell, vol. 15,
no. 3, pp. 195–206, 2009.
[82] C. Mayer, S. Darb-Esfahani, A. Meyer et al., “Neutrophil
granulocytes in ovarian cancer—induction of epithelial-to-
mesenchymal-transition and tumor cell migration,” Journal of
Cancer, vol. 7, no. 5, pp. 546–554, 2016.
[83] M. Ricciardi, M. Zanotto, G. Malpeli et al., “Epithelial-to-
mesenchymal transition (EMT) induced by inflammatory
priming elicits mesenchymal stromal cell-like immune-mod-
ulatory properties in cancer cells,” British Journal of Cancer, vol.
112, pp. 1067–1075, 2015.
[84] M. Kmieciak, K. L. Knutson, C. I. Dumur, and M. H. Manjili,
“HER-2/neu antigen loss and relapse of mammary carcinoma
are actively induced by T cell-mediated anti-tumor immune
responses,” European Journal of Immunology, vol. 37, no. 3, pp.
675–685, 2007.
[85] K. L. Knutson, H. Lu, B. Stone et al., “Immunoediting of cancers
may lead to epithelial to mesenchymal transition,” Journal of
Immunology, vol. 177, no. 3, pp. 1526–1533, 2006.
[86] A. Lo´pez-Soto, L. Huergo-Zapico, J. A. Galvan et al., “Epithe-
lial-mesenchymal transition induces an antitumor immune
response mediated by NKG2D receptor,” Journal of Immunol-
ogy, vol. 190, no. 8, pp. 4408–4419, 2013.
[87] L. Huergo-Zapico, A. Acebes-Huerta, A. Lo´pez-Soto, M. Villa-
A´lvarez, A. P.Gonzalez-Rodriguez, and S.Gonzalez, “Molecular
bases for the regulation of NKG2D ligands in cancer,” Frontiers
in Immunology, vol. 5, article 106, 2014.
[88] X.-H. Chen, Z.-C. Liu, G. Zhang et al., “TGF-𝛽 and EGF
induced HLA-I downregulation is associated with epithelial-
mesenchymal transition (EMT) through upregulation of snail
in prostate cancer cells,” Molecular Immunology, vol. 65, no. 1,
pp. 34–42, 2015.
[89] M. Balsamo, W. Vermi, M. Parodi et al., “Melanoma cells
become resistant to NK-cell-mediated killing when exposed to
NK-cell numbers compatible with NK-cell infiltration in the
tumor,”European Journal of Immunology, vol. 42, no. 7, pp. 1833–
1842, 2012.
[90] J. M. Taube, R. A. Anders, G. D. Young et al., “Colocalization
of inflammatory response with B7-H1 expression in human
melanocytic lesions supports an adaptive resistancemechanism
of immune escape,” Science Translational Medicine, vol. 4, no.
127, Article ID 127ra37, 2012.
[91] D. M. Pardoll, “The blockade of immune checkpoints in cancer
immunotherapy,”Nature Reviews Cancer, vol. 12, no. 4, pp. 252–
264, 2012.
[92] J. M. Taube, G. D. Young, T. L. McMiller et al., “Differential
expression of immune-regulatory genes associated with PD-L1
display in melanoma: implications for PD-1 pathway blockade,”
Clinical Cancer Research, vol. 21, no. 17, pp. 3969–3976, 2015.
[93] R. Bellucci, A. Martin, D. Bommarito et al., “Interferon-𝛾-
induced activation of JAK1 and JAK2 suppresses tumor cell
susceptibility toNKcells throughupregulation of PD-L1 expres-
sion,”OncoImmunology, vol. 4, no. 6, Article ID e1008824, 2015.
[94] L. Chen, D. L. Gibbons, S. Goswami et al., “Metastasis is
regulated via microRNA-200/ZEB1 axis control of tumour
cell PD-L1 expression and intratumoral immunosuppression,”
Nature Communications, vol. 5, article 5241, 2014.
[95] N.-K. V. Cheung and M. A. Dyer, “Neuroblastoma: develop-
mental biology, cancer genomics and immunotherapy,” Nature
Reviews Cancer, vol. 13, no. 6, pp. 397–411, 2013.
[96] C. Bottino, A. Dondero, F. Bellora et al., “Natural killer cells
and neuroblastoma: tumor recognition, escape mechanisms,
and possible novel immunotherapeutic approaches,” Frontiers
in Immunology, vol. 5, article 56, 2014.
[97] A. Dondero, F. Pastorino, M. Della Chiesa et al., “PD-L1 expres-
sion in metastatic neuroblastoma as an additional mechanism
for limiting immune surveillance,”OncoImmunology, vol. 5, no.
1, Article ID e1064578, 2016.
[98] S. Burke, T. Lakshmikanth, F. Colucci, and E. Carbone, “New
views on natural killer cell-based immunotherapy for mela-
noma treatment,” Trends in Immunology, vol. 31, no. 9, pp. 339–
345, 2010.
[99] M. H. Sandel, F.M. Speetjens, A. G.Menon et al., “Natural killer
cells infiltrating colorectal cancer and MHC class I expression,”
Molecular Immunology, vol. 42, no. 4, pp. 541–546, 2005.
[100] G. Esendagli, K. Bruderek, T. Goldmann et al., “Malignant and
non-malignant lung tissue areas are differentially populated by
natural killer cells and regulatory T cells in non-small cell lung
cancer,” Lung Cancer, vol. 59, no. 1, pp. 32–40, 2008.
[101] D. R. Strayer, W. A. Carter, S. D. Mayberry, E. Pequignot, and I.
Brodsky, “Low natural cytotoxicity of peripheral blood mono-
nuclear cells in individuals with high familial incidence of
cancer,” Cancer Research, vol. 44, no. 1, pp. 370–374, 1984.
[102] G. Sconocchia, R. Arriga, L. Tornillo, L. Terracciano, S. Ferrone,
and G. C. Spagnoli, “Melanoma cells inhibit NK cell functions,”
Cancer Research, vol. 72, no. 20, pp. 5428–5430, 2012.
[103] P.A.Albertsson, P.H. Basse,M.Hokland et al., “NKcells and the
tumour microenvironment: implications for NK-cell function
and anti-tumour activity,” Trends in Immunology, vol. 24, no. 11,
pp. 603–609, 2003.
[104] J. J. Campbell, S. Qin, D. Unutmaz et al., “Unique subpopula-
tions of CD56+ NK and NK-T peripheral blood lymphocytes
identified by chemokine receptor expression repertoire,” Jour-
nal of Immunology, vol. 166, no. 11, pp. 6477–6482, 2001.
12 Journal of Immunology Research
[105] M. Inngjerdingen, B. Damaj, and A. A. Maghazachi, “Expres-
sion and regulation of chemokine receptors in human natural
killer cells,” Blood, vol. 97, no. 2, pp. 367–375, 2001.
[106] G. Bernardini, A. Gismondi, and A. Santoni, “Chemokines and
NK cells: regulators of development, trafficking and functions,”
Immunology Letters, vol. 145, no. 1-2, pp. 39–46, 2012.
[107] F. Casilli, A. Bianchini, I. Gloaguen et al., “Inhibition of interleu-
kin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor
of the chemokine receptors CXCR1 and CXCR2,” Biochemical
Pharmacology, vol. 69, no. 3, pp. 385–394, 2005.
[108] M. J. Robertson, “Role of chemokines in the biology of natural
killer cells,” Journal of Leukocyte Biology, vol. 71, no. 2, pp. 173–
183, 2002.
[109] D. L. Hodge, W. B. Schill, J. M. Wang et al., “IL-2 and IL-12 alter
NK cell responsiveness to IFN-𝛾-inducible protein 10 by down-
regulating CXCR3 expression,” Journal of Immunology, vol. 168,
no. 12, pp. 6090–6098, 2002.
[110] S. Parolini, A. Santoro, E. Marcenaro et al., “The role of chem-
erin in the colocalization of NK and dendritic cell subsets into
inflamed tissues,” Blood, vol. 109, no. 9, pp. 3625–3632, 2007.
[111] J. Barlic, J. M. Sechler, and P. M. Murphy, “IL-15 and IL-2
oppositely regulate expression of the chemokine receptor
CX3CR1,” Blood, vol. 102, no. 10, pp. 3494–3503, 2003.
[112] R. B. Mailliard, S. M. Alber, H. Shen et al., “IL-18-induced
CD83+CCR7+ NK helper cells,” The Journal of Experimental
Medicine, vol. 202, no. 7, pp. 941–953, 2005.
[113] M. Wendel, I. E. Galani, E. Suri-Payer, and A. Cerwenka,
“Natural killer cell accumulation in tumors is dependent on
IFN-𝛾 and CXCR3 ligands,” Cancer Research, vol. 68, no. 20, pp.
8437–8445, 2008.
[114] F. Vianello, N. Papeta, T. Chen et al., “Murine B16 melanomas
expressing high levels of the chemokine stromal-derived factor-
1/CXCL12 induce tumor-specific T cell chemorepulsion and
escape from immune control,”The Journal of Immunology, vol.
176, no. 5, pp. 2902–2914, 2006.
[115] R. K. Pachynski, B. A. Zabel, H. E. Kohrt et al., “The
chemoattractant chemerin suppresses melanoma by recruiting
natural killer cell antitumor defenses,” Journal of Experimental
Medicine, vol. 209, no. 8, pp. 1427–1435, 2012.
[116] J. O. Thomas and A. A. Travers, “HMG1 and 2, and related
‘architectural’ DNA-binding proteins,” Trends in Biochemical
Sciences, vol. 26, no. 3, pp. 167–174, 2001.
[117] H. Lee,N. Shin,M. Song et al., “Analysis of nuclear highmobility
group box 1 (HMGB1)-binding proteins in colon cancer cells:
clustering with proteins involved in secretion and extranuclear
function,” Journal of Proteome Research, vol. 9, no. 9, pp. 4661–
4670, 2010.
[118] H. S. Hreggvidsdottir, T. O¨stberg, H. Wa¨ha¨maa et al., “The
alarmin HMGB1 acts in synergy with endogenous and exoge-
nous danger signals to promote inflammation,” Journal of
Leukocyte Biology, vol. 86, no. 3, pp. 655–662, 2009.
[119] A. Didangelos, M. Puglia, M. Iberl, C. Sanchez-Bellot, B. Ros-
chitzki, and E. J. Bradbury, “High-throughput proteomics reveal
alarmins as amplifiers of tissue pathology and inflammation
after spinal cord injury,” Scientific Reports, vol. 6, Article ID
21607, 2016.
[120] J. Thorburn, A. E. Frankel, and A. Thorburn, “Regulation of
HMGB1 release by autophagy,”Autophagy, vol. 5, no. 2, pp. 247–
249, 2009.
[121] M. T. Lotze, H. J. Zeh, A. Rubartelli et al., “The grateful dead:
damage-associated molecular pattern molecules and reduc-
tion/oxidation regulate immunity,” Immunological Reviews, vol.
220, no. 1, pp. 60–81, 2007.
[122] H. Yang, P. Lundba¨ck, L. Ottosson et al., “Redoxmodification of
cysteine residues regulates the cytokine activity of highmobility
group box-1 (HMGB1),” Molecular Medicine, vol. 18, no. 2, pp.
250–259, 2012.
[123] E. Venereau, M. Casalgrandi, M. Schiraldi et al., “Mutually
exclusive redox forms of HMGB1 promote cell recruitment
or proinflammatory cytokine release,” Journal of Experimental
Medicine, vol. 209, no. 9, pp. 1519–1528, 2012.
[124] R. R. Kew, M. Penzo, D. M. Habiel, and K. B. Marcu, “The
IKK𝛼-dependent NF-𝜅B p52/RelB noncanonical pathway is
essential to sustain a CXCL12 autocrine loop in cells migrating
in response toHMGB1,”The Journal of Immunology, vol. 188, no.
5, pp. 2380–2386, 2012.
[125] M. Schiraldi, A. Raucci, L. M. Mun˜oz et al., “HMGB1 promotes
recruitment of inflammatory cells to damaged tissues by form-
ing a complex with CXCL12 and signaling via CXCR4,” The
Journal of Experimental Medicine, vol. 209, no. 3, pp. 551–563,
2012.
[126] D. Yang, Q. Chen, H. Yang, K. J. Tracey, M. Bustin, and J. J.
Oppenheim, “High mobility group box-1 protein induces the
migration and activation of human dendritic cells and acts as
an alarmin,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 59–
66, 2007.
[127] H. Yang, H. S. Hreggvidsdottir, K. Palmblad et al., “A critical
cysteine is required for HMGB1 binding to toll-like receptor 4
and activation of macrophage cytokine release,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 107, no. 26, pp. 11942–11947, 2010.
[128] H. Kazama, J.-E. Ricci, J. M. Herndon, G. Hoppe, D. R. Green,
and T. A. Ferguson, “Induction of immunological tolerance by
apoptotic cells requires caspase-dependent oxidation of high-
mobility group box-1 protein,” Immunity, vol. 29, no. 1, pp. 21–
32, 2008.
[129] D. Tang, R. Kang, C.-W. Cheh et al., “HMGB1 release and redox
regulates autophagy and apoptosis in cancer cells,” Oncogene,
vol. 29, no. 38, pp. 5299–5310, 2010.
[130] T. Bonaldi, F. Talamo, P. Scaffidi et al., “Monocytic cells hypera-
cetylate chromatin protein HMGB1 to redirect it towards
secretion,” The EMBO Journal, vol. 22, no. 20, pp. 5551–5560,
2003.
[131] B. Lu, D. J. Antoine, K. Kwan et al., “JAK/STAT1 signaling
promotes HMGB1 hyperacetylation and nuclear translocation,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 111, no. 8, pp. 3068–3073, 2014.
[132] K. Davis, S. Banerjee, A. Friggeri, C. Bell, E. Abraham, and
M. Zerfaoui, “Poly(ADP-Ribosyl)ation of high mobility group
box 1 (HMGB1) protein enhances inhibition of efferocytosis,”
Molecular Medicine, vol. 18, no. 3, pp. 359–369, 2012.
[133] X. Zhang, D. Wheeler, Y. Tang et al., “Calcium/calmodulin-
dependent protein kinase (CaMK) IVmediates nucleocytoplas-
mic shuttling and release of HMGB1 during lipopolysaccharide
stimulation of macrophages,” The Journal of Immunology, vol.
181, no. 7, pp. 5015–5023, 2008.
[134] Y. J. Oh, J. H. Youn, Y. Ji et al., “HMGB1 is phosphorylated
by classical protein kinase C and is secreted by a calcium-
dependent mechanism,” Journal of Immunology, vol. 182, no. 9,
pp. 5800–5809, 2009.
Journal of Immunology Research 13
[135] H. Lee, M. Park, N. Shin et al., “High mobility group box-1 is
phosphorylated by protein kinase C zeta and secreted in colon
cancer cells,” Biochemical and Biophysical Research Communi-
cations, vol. 424, no. 2, pp. 321–326, 2012.
[136] J. Taira and Y. Higashimoto, “Evaluation of in vitro properties
of predicted kinases that phosphorylate serine residues within
nuclear localization signal 1 of high mobility group box 1,”
Journal of Peptide Science, vol. 20, no. 8, pp. 613–617, 2014.
[137] H.Wa¨ha¨maa, H. Schierbeck, H. S. Hreggvidsdottir et al., “High
mobility group box protein 1 in complex with lipopolysaccha-
ride or IL-1 promotes an increased inflammatory phenotype in
synovial fibroblasts,” Arthritis Research andTherapy, vol. 13, no.
4, article R136, 2011.
[138] H. S. Hreggvidsdo´ttir, A. M. Lundberg, A.-C. Aveberger, L.
Klevenvall, U. Andersson, and H. E. Harris, “High mobility
group box protein 1 (HMGB1)-partner molecule complexes
enhance cytokine production by signaling through the partner
molecule receptor,” Molecular Medicine, vol. 18, no. 2, pp. 224–
230, 2012.
[139] G. Li, X. Liang, and M. T. Lotze, “HMGB1: the central cytokine
for all lymphoid cells,” Frontiers in Immunology, vol. 4, article
68, 2013.
[140] S. Chiba, M. Baghdadi, H. Akiba et al., “Tumor-infiltrating
DCs suppress nucleic acid-mediated innate immune responses
through interactions between the receptor TIM-3 and the
alarmin HMGB1,” Nature Immunology, vol. 13, no. 9, pp. 832–
842, 2012.
[141] M. Pedrazzi, M. Averna, B. Sparatore et al., “Potentiation of
NMDA receptor-dependent cell responses by extracellular high
mobility group box 1 protein,” PLoS ONE, vol. 7, no. 8, Article
ID e44518, 2012.
[142] S. Qin, H. Wang, R. Yuan et al., “Role of HMGB1 in apoptosis-
mediated sepsis lethality,”The Journal of ExperimentalMedicine,
vol. 203, no. 7, pp. 1637–1642, 2006.
[143] H.Wang, O. Bloom,M. Zhang et al., “HMG-1 as a late mediator
of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp.
248–251, 1999.
[144] M. Parodi, M. Pedrazzi, C. Cantoni et al., “Natural Killer (NK)/
melanoma cell interaction induces NK-mediated release of
chemotactic High Mobility Group Box-1 (HMGB1) capable of
amplifying NK cell recruitment,” OncoImmunology, vol. 4, no.
12, 2015.
[145] I. Ito, J. Fukazawa, and M. Yoshida, “Post-translational methy-
lation of high mobility group box 1 (HMGB1) causes its cyto-
plasmic localization in neutrophils,” The Journal of Biological
Chemistry, vol. 282, no. 22, pp. 16336–16344, 2007.
[146] M. M. Rabadi, M.-C. Kuo, T. Ghaly et al., “Interaction between
uric acid and HMGB1 translocation and release from endothe-
lial cells,” American Journal of Physiology—Renal Physiology,
vol. 302, no. 6, pp. F730–F741, 2012.
[147] K. Feghali, K. Iwasaki, K. Tanaka et al., “Human gingival fibrob-
lasts release high-mobility group box-1 protein through active
and passive pathways,”Oral Microbiology and Immunology, vol.
24, no. 4, pp. 292–298, 2009.
[148] Y.Moriwaka, Y. Luo, H. Ohmori et al., “HMGB1 attenuates anti-
metastatic defense of the lymph nodes in colorectal cancer,”
Pathobiology, vol. 77, no. 1, pp. 17–23, 2010.
[149] F. Berthelot, L. Fattoum, S. Casulli, J. Gozlan, V. Mare´chal, and
C. Elbim, “The effect of HMGB1, a damage-associated molecu-
lar pattern molecule, on polymorphonuclear neutrophil migra-
tion depends on its concentration,” Journal of Innate Immunity,
vol. 4, no. 1, pp. 41–58, 2012.
[150] J. L. Guerriero, D. Ditsworth, J. M. Catanzaro et al., “DNA alky-
lating therapy induces tumor regression through an HMGB1-
mediated activation of innate immunity,” The Journal of
Immunology, vol. 186, no. 6, pp. 3517–3526, 2011.
[151] P.-L. Liu, J.-R. Tsai, J.-J. Hwang et al., “High-mobility group box
1-mediatedmatrixmetalloproteinase-9 expression in non-small
cell lung cancer contributes to tumor cell invasiveness,” Amer-
ican Journal of Respiratory Cell and Molecular Biology, vol. 43,
no. 5, pp. 530–538, 2010.
[152] G.-L. Yang, L.-H. Zhang, J.-J. Bo et al., “Increased expression
of HMGB1 is associated with poor prognosis in human bladder
cancer,” Journal of Surgical Oncology, vol. 106, no. 1, pp. 57–61,
2012.
[153] X. Yao, G. Zhao, H. Yang, X. Hong, L. Bie, and G. Liu,
“Overexpression of high-mobility group box 1 correlates with
tumor progression and poor prognosis in human colorectal car-
cinoma,” Journal of Cancer Research and Clinical Oncology, vol.
136, no. 5, pp. 677–684, 2010.
[154] C. A.Wild, S. Brandau, R. Lotfi et al., “HMGB1 is overexpressed
in tumor cells and promotes activity of regulatory T cells in
patients with head and neck cancer,”Oral Oncology, vol. 48, no.
5, pp. 409–416, 2012.
[155] C. B. Zhao, J.M. Bao, Y. J. Lu et al., “Co-expression of RAGE and
HMGB1 is associated with cancer progression and poor patient
outcome of prostate cancer,” American Journal of Cancer
Research, vol. 4, no. 4, pp. 369–377, 2014.
[156] L. Zhang, J. Han, H. Wu et al., “The association of HMGB1
expression with clinicopathological significance and prognosis
in hepatocellular carcinoma: a meta-analysis and literature
review,” PLoS ONE, vol. 9, no. 10, Article ID e110626, 2014.
[157] G. Bao, Q. Qiao, H. Zhao, and X. He, “Prognostic value of
HMGB1 overexpression in resectable gastric adenocarcinomas,”
World Journal of Surgical Oncology, vol. 8, article 52, 2010.
[158] Q. Li, J. Li, T. Wen et al., “Overexpression of HMGB1 in
melanoma predicts patient survival and suppression of HMGB1
induces cell cycle arrest and senescence in association with
p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-
dependent pathway,” Oncotarget, vol. 5, no. 15, pp. 6387–6403,
2014.
[159] W. Yan, Y. Chang, X. Liang et al., “High-mobility group box 1
activates caspase-1 and promotes hepatocellular carcinoma
invasiveness and metastases,” Hepatology, vol. 55, no. 6, pp.
1863–1875, 2012.
[160] J. R. van Beijnum, P. Nowak-Sliwinska, E. van Den Boezem, P.
Hautvast, W. A. Buurman, and A. W. Griffioen, “Tumor angio-
genesis is enforced by autocrine regulation of high-mobility
group box 1,” Oncogene, vol. 32, no. 3, pp. 363–374, 2013.
[161] S. Mitola, M. Belleri, C. Urbinati et al., “Cutting edge: extra-
cellular high mobility group box-1 protein is a proangiogenic
cytokine,” Journal of Immunology, vol. 176, no. 1, pp. 12–15, 2006.
[162] S. Jost, U. Y. Moreno-Nieves, W. F. Garcia-Beltran et al., “Dys-
regulated Tim-3 expression on natural killer cells is associated
with increased Galectin-9 levels in HIV-1 infection,” Retrovirol-
ogy, vol. 10, article 74, 2013.
[163] A. A. Boldyrev, E. A. Bryushkova, and E. A. Vladychenskaya,
“NMDA receptors in immune competent cells,” Biochemistry,
vol. 77, no. 2, pp. 128–134, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
